Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythropoietin for Cognitive Side-effects of ECT
NCT03339596Phase 2Completed
- Start
- Jun 2017
- Primary completion
- Jan 2023
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
A Phase 2 trial of epoetin alfa in cognitive impairment. Started Jun 2017; status: completed.
02
Drugs
epoetin alfa
03
Conditions
cognitive impairment
Beyond the preview
Go deeper on NCT03339596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03339596.